title: Management of living donor liver transplant patients using twice-daily 4-hour intravenous cyclosporine therapy.
abstract: Oral administration of cyclosporine (CsA) is the currently favored route in most liver transplant centers. From October 1998 to January 2008, 86 living donor liver transplantations (LDLTs) were performed in 85 patients (46 adults and 39 children) at our institution. Seventy-three patients received tacrolimus (Tac), and 12 intravenous CsA twice daily at a dose of 3 mg/kg/d as a 4-hour continuous infusion. Thirteen of 73 Tac-based patients were switched to CsA because of side effects. Five were switched to intravenous CsA because they were unable to take the drug orally because of severe Tac-related complications. The remaining eight patients switched to oral CsA. We evaluated patients (11 adults and three children), including 12 with induction therapy and two with conversion therapy within 2 weeks of LDLT. The patients were given a 4-hour intravenous infusion of CsA at an initial dose of 3 mg/kg/d. Stable and adequate blood CsA concentrations were achieved by 4-hour intravenous CsA administration. Among several factors, only graft-to-recipient weight ratio (r = .743, P < .0001) showed significant correlations with initial blood CsA concentration. No adverse effects were observed after intravenous CsA. No patients developed biopsy-proven acute cellular rejection (ACR) during intravenous CsA administration, whereas two patients had histopathologically diagnosed episodes of ACR after conversion from intravenous to oral CsA. Our findings suggest that immediate administration of a 4-hour intravenous infusion of CsA at an initial dose of 3 mg/kg/d is practical and effective for routine clinical use.
authors.affiliation: Advanced Surgical Science and Technology Division, Department of Surgery, Graduate School of Medicine, University of Tohoku, Sendai, Japan. satokazu@mail.tains.tohoku.ac.jp
authors.forename: K
authors.initials: K
authors.lastname: Sato
authors.forename: T
authors.initials: T
authors.lastname: Iwane
authors.forename: S
authors.initials: S
authors.lastname: Sekiguchi
authors.forename: A
authors.initials: A
authors.lastname: Nakamura
authors.forename: Y
authors.initials: Y
authors.lastname: Akamatsu
authors.forename: N
authors.initials: N
authors.lastname: Kawagishi
authors.forename: S
authors.initials: S
authors.lastname: Miyagi
authors.forename: I
authors.initials: I
authors.lastname: Takeda
authors.forename: A
authors.initials: A
authors.lastname: Sato
authors.forename: K
authors.initials: K
authors.lastname: Fujimori
authors.forename: S
authors.initials: S
authors.lastname: Satomi
mesh_terms: D000328:Adult; D002648:Child; D016572:Cyclosporine / Q000008:administration & dosage / Q000097:blood* / Q000493:pharmacokinetics / Q000627:therapeutic use*; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics / Q000627:therapeutic use; D007262:Infusions, Intravenous; D007441:Intubation, Gastrointestinal; D016031:Liver Transplantation / Q000276:immunology*; D019520:Living Donors; D012189:Retrospective Studies; D016559:Tacrolimus / Q000008:administration & dosage / Q000627:therapeutic use
chemical_list: D007166:Immunosuppressive Agents; D016572:Cyclosporine; D016559:Tacrolimus